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Objectives: This study aims to understand unmet medical needs despite 
available treatment options of venous thromboembolism (VTE) treatment in 
Europe. MethOds: This retrospective cohort study included data from physi-
cians (376 general practitioners and 307 specialists) in France, Germany, Italy, 
and Spain, who completed case report forms for the next 3-4 patients seen in 
consultation meeting inclusion criteria. Patients were assigned to mutually 
exclusive groups based on a hierarchy (vitamin K antagonist (VKA), rivaroxa-
ban, low-molecular-weight-heparin (LMWH), aspirin, other anti-coagulants, no 
known treatment, respectively) determined by treatment data (dosing, start/end 
dates, and prescription duration and prescriber information, either in hospital 
or at discharge, following VTE, or as new treatment for first-time VTE event). 
Logistic regression with backward elimination identified significant predictors 
of treatment allocation. Results: Patients’ mean age (total n= 2184) was 61.3 
years (SD= 14.3) and 47.4% were females. The hierarchy of treatments revealed 
that 63.1% of patients were using VKA, 30.6% using rivaroxaban or LMWH but no 
VKA, and 6.2% using other combinations. Mean treatment period was higher for 
VKA (168 days) than for rivaroxaban (139 days) or LMWH (46 days) patients. LMWH 
treatment was significantly more common than VKA among cancer patients (odds 
ratio (OR):2.35, P< .001), but less likely among pulmonary embolism or deep vein 
thrombosis patients with (OR:0.35, P= .001) or without complications (OR:0.33, 
P= .001), hospitalization for first VTE (OR:0.32, P< .001), and hip/knee replacement 
(OR:0.39, P= .028). Predictors of VKA vs. rivaroxaban included: more months since 
initial VTE event (OR:1.06, P< .001), no hormone replacement therapy (OR:5.83, 
P< .001), no chronic heart failure (OR:2.09, P= .001), and age of 40+ (OR:1.61, 
P= .03). cOnclusiOns: Treatment patterns in the European Union show that VKA 
is a common treatment for VTE in addition to other anticoagulants. Attention to 
risk factors can play a major role in determining continuation of therapy which 
is likely to reduce VTE recurrence.
Muscular-skeletal DisorDers – clinical outcomes studies
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Objectives: A signal of bisphosphonate-related cardiac valve calcification lead-
ing to cardiac valve insufficiency was detected in the European adverse event 
monitoring system (EudraVigilance); however no signal detection activity was 
conducted in the US. This pharmacovigilance analysis investigates and relation-
ship between bisphosphonates and aortic and mitral valve calcification in the FDA 
Adverse Event Reporting System (FAERS). MethOds: Bisphosphonate-related 
adverse event reports submitted to FAERS between 1997 and 2013 were used to 
investigate the disproportional reporting of cardiac valve disorders (CVD) in rela-
tion to bisphosphonates therapy, including aortic and mitral valve calcification. 
Multi-item Gamma Poisson Shrinker data mining algorithm was used to calculate 
Empirical Bayes Geometric Mean (EBGM) and corresponding 95% confidence interval 
as disproportionality measures. Signals that warrant further review are defined 
as measures with confidence interval lower limit≥ 2.0. The Anatomical Chemical 
and Therapeutic classification was used to define bisphosphonate exposure, and 
the Medical Dictionary for Regulatory Activities, Preferred Term coding hierar-
chy was used to define cardiac valve calcification. Results: A total of 2,010 CVD 
events were submitted for bisphosphonates. Of those, 116 events were for cardiac 
valve calcification, affecting aortic valve (n= 32); mitral valve (n= 83); and pulmo-
nary valve (n= 1). Signals were detected for alendronate (aortic: n= 8, EBGM= 3.7, 
95%CI= 2.03-6.34; mitral: n= 15, EBGM= 3.99, 95%CI= 2.58-5.96); pamidronate (aortic: 
n= 7, EBGM= 9.94, 95%CI= 3.27-30.3; mitral: n= 25, EBGM= 36.8, 95%CI= 26.1-50.6); and 
Zoledronate (aortic: n= 13, EBGM= 4.44, 95%CI= 2.77-6.86; mitral: n= 39, EBGM= 7.23, 
95%CI= 5.45-9.58). No signal was detected for ibadronate (aortic: n= 1, EBGM= 0.92, 
95%CI= 0.21-2.92; mitral: n= 2, EBGM= 1.02, 95%CI= 0.32-2.58) and risedronate (aor-
tic: n= 3, EBGM= 2.6, 95%CI= 0.99-5.9; mitral: n= 2, EBGM= 1.43, 95%CI= 0.45-3.61; pul-
monary: n= 1, EBGM= 1.36, 95%CI= 0.3-4.38). cOnclusiOns: Treatment with some 
bisphosphonates might be associated with aortic and mitral valve calcification. It 
might be necessary for prescribers to monitor patients for CVD before and periodi-
cally during bisphosphonates therapy. Signal clarification and evaluation activities 
by pharmacoepidemiologic studies are recommended.
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Objectives: The aim of this network meta-analysis was to compare the safety of 
tofacitinib to biological DMARDs for treatment of rheumatoid arthritis in patient 
with inadequate response to methotrexate. MethOds: We performed an overview 
of systematic reviews that evaluated biological DMARDs or tofacitinib for treat-
ment of rheumatoid arthritis patients with inadequate response to methotrexate. 
The searching was carried out using the database of MEDLINE, EMBASE, Lilacs, 
COCHRANE, DARE and HTA restrictive to systematic review published in the last 
five years. The strategy of search was the similar to guideline of rheumatoid arthritis 
of the Ministry of Health of Colombia. Two researchers selected independently the 
studies and extracted the data. La risk of bias of systematic review was assessed 
with AMSTAR and ISPOR tools. The clinical trials were evaluated with The Cochrane 
Collaboration’s tool for assessing risk of bias . Bayesian mixed treatment compari-
son method was applied for the pairwise comparison of treatments, where the 
common comparator was methotrexate. The outcomes were occurrence of serious 
adverse events, serious infections and withdrawal due to adverse event. Results: 
treatment initiation. The rates of TM were significantly different across ADCs; 
angiotensin converting enzyme inhibitor and angiotensin receptor blocker users 
were less likely to receive TMs compared to other drug classes. The mean time-
to-TM was > 100 days for patients adding or uptitrating medications, and > 150 
days for those switching or downtitrating medications. The likelihood of discon-
tinuation was significantly lower for patients intensifying treatment by adding 
medications vs. those uptitrating dose (HR= 0.765; CI: 0.701-0.834). cOnclusiOns: 
TMs are common among newly treated hypertensive patients. The rates of TM 
vary significantly across ADCs. In the real-world, TMs occur much later than the 
30-day time-line recommended by clinical guidelines. Addition of drugs may be a 
preferred approach vs. uptitrating drug dose for intensifying treatment of patients 
who are at a high risk of treatment discontinuation.
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Objectives: objective: Despite the efficacy and safety of statins, real-world data 
suggest they are suboptimally used among dyslipidemic patients. The current 
study sought to describe patterns of statin utilization among high cardiovascular 
(CV)-risk patients initiating statin therapy. MethOd: Methods: Adult patients (≥ 18 
years) with continuous enrollment who were newly initiating statins were identi-
fied from the Truven MarketScan Research databases (01/2007-06/2013). Patients 
were selected for and stratified into 1 of 5 mutually exclusive, high CV-risk–based 
hierarchical categories: recent acute CV event ( hospitalization for acute coronary 
syndrome [ACS] or other CV event within 90 days of index), coronary heart disease 
(CHD), ischemic stroke, peripheral vascular disease/peripheral artery disease (PVD/
PAD), and diabetes. Descriptive statistics and time-to-event analyses were used to 
measure proportion of days covered (PDC), time to discontinuation, and hospitaliza-
tion rates. Results: results: Among 541,221 high CV-risk patients, 61% were in the 
diabetes cohort, followed by recent acute CV event (26%), PVD/PAD (5%), CHD (4%), 
and ischemic stroke (4%). High-intensity statins (atorvastatin 40/80 mg, rosuvastatin 
20/40 mg, simvastatin 80 mg) were initiated in 15% of patients, with the percentages 
varying among subgroups (10% [diabetes] to 31% [ACS]). More than 20% of high-
intensity statin initiators switched to a moderate- to low-intensity statin (range, 
19% [PVD/PAD] to 28% [other CV event]). The PDC ranged from 56% (diabetes) to 
66% (ACS). Median time to statin discontinuation among high CV-risk patients was 
approximately 15 months. Median time to discontinuation among patients receiv-
ing high-intensity versus moderate- to low-intensity statin was 21 months and 15 
months, respectively. At 1 year, Kaplan-Meier estimates of cumulative event rates 
for CV-related hospitalizations were lowest in the diabetes cohort and highest for 
patients with recent ACS hospitalization (4% and 22%, respectively). cOnclusiOns: 
conclusion: Low PDC and discontinuation of statin therapy were observed among 
high CV-risk patients. Interventional opportunities to ensure better therapy man-
agement are warranted.
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Objectives: In patients with spontaneous intracerebral hemorrhage (ICH), cur-
rent guidelines recommend managing elevated blood pressure (BP) with inter-
mittent or continuous infusion of intravenous medications. The purpose of this 
retrospective observational study is to evaluate the clevidipine (CLV) usage pat-
terns and patient outcomes of continuous infusion intravenous antihyperten-
sive agents (IVAH) compared to other agents available. MethOds: Study data 
were extracted from the Premier hospital database. ICH patients were identified 
by primary diagnosis ICD-9 CM codes of 431 (ICH) or 432 (other or unspecified 
ICH) and a final MS-DRG of 64, 65, 66 (Intracranial hemorrhage or cerebral infarc-
tion). Patients who received clevidipine, nicardipine, or nitroprusside during the 
first two days of admission between January 2009 and June 2014 were included. 
Baseline demographics, outcomes, and costs were evaluated and propensity score 
matching comparing CLV to nicardipine (NIC) and CLV to nitroprusside (SNP) was 
performed to control for confounders. Results: 165 clevidipine, 15910 nicardi-
pine, and 1091 nitroprusside inpatients from 520 US hospitals met the inclusion 
criteria. Treatment pattern analysis showed nitroprusside usage decreased from 
15.8% in 2009 to 1.3% in 2014, while NIC and CLV usage increased over the same 
time; CLV from 0.8% to 2.7% . After propensity matching, 126 patients remained 
in each group for the CLV-NIC pair and 90 patients in the CLV-SNP pair. Mortality 
rates were similar in both comparisons at 27.8% (CLV) vs 28.6% (NIC) and 31.1% 
(CLV) vs. 37.8% (SNP). After excluding in-hospital deaths, mean length of stay 
was 7.8 days (CLV) vs 8.8 days (NIC) and 8.0 days (CLV) vs 8.2 days (SNP). Inflation 
adjusted mean total costs were $16903 (CLV) vs $18634 (NIC) and $15972 (CLV) vs 
$15965 (SNP). cOnclusiOns: Although CLV is < 3% of use in this sample, PSM 
demonstrates similar outcomes in comparison with NIC and SNP.
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Objectives: Denosumab is a human monoclonal antibody against receptor acti-
vator of nuclear factor-kB ligand (RANKL), which can be used for osteoporosis as an 
antiresorptive agent. The aim of this study was to evaluate the efficacy and safety 
of denosumab for the treatment of postmenopausal osteoporosis by performing 
a meta-analysis. MethOds: Pubmed, EMBASE, the Cochrane Central Register 
of Controlled Trials, and other trial registries through July 2014 were searched. 
Inclusion criteria were randomized, placebo-controlled clinical trials on patients 
with postmenopausal osteoporosis, 60mg of denosumab every 6 months, con-
sistent time framework, and derivable outcomes for incidences of new vertebral, 
nonvertebral fractures, and adverse events. A meta-analysis using fixed-effects 
model was conducted to calculate pooled relative risks with a 95% confidence 
interval. Heterogeneity across studies was also assessed. Results: Six RCTs 
involving 9134 patients were included. The results showed that denosumab was 
associated with a significant reduction in new vertebral fractures risk (RR= 0.325, 
95%CI 0.256 to 0.412, p< 0.001). A decreased risk of nonvertebral fractures was also 
observed (RR= 0.789, 95%CI 0.670 to 0.928, p= 0.004). As compared to the placebo 
arm, the denosumab arm showed no evidence of significant risk of total adverse 
events [RR= 1.003, 95%CI 0.991 to 1.015], serious adverse events [RR= 1.042, 95%CI 
0.967 to 1.124], and fatal adverse events [RR= 0.785, 95%CI 0.557 to 1.067]. In addi-
tion, the incidence rates of all treatment-related adverse events and dropouts 
due to adverse events were not significant between the denosumab and placebo 
arms. cOnclusiOns: The efficacy of denosumab on fracture risk reduction and 
its safety has not yet been systematically proved. However, results of this meta-
analysis showed that denosumab was associated with a significant reduction in 
the risk of vertebral and nonvertebral fractures in patients with postmenopausal 
osteoporosis. No evidence of increased risk in serious, fatal and all treatment-
related adverse events were detected.
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Objectives: Describe the adverse drug reactions (ADR) and their incidence in 
patients with rheumatoid arthritis who were treated in the Colombian Heath 
System. MethOds: Retrospective cohort study using information from all 
patients who were diagnosed with rheumatoid arthritis and attended Specialized 
Institution centers in the cities of Bogotá, Cali, Manizales, Medellin and Pereira 
between December 1st, 2009 and August 30th, 2013. The ADRs were obtained from 
medical records and the pharmacovigilance system register and were sorted by 
frequency and affected tissue according to WHO Adverse Reaction Terminology 
(WHO-ART). Results: A total of 949 ADR reports were obtained from 419 patients 
with an incidence of 32.8 ADRs per 100 patient-years; these were from a cohort 
of 1,364 users followed for an average of 23.8±12.9 months. There was a female 
preponderance (n= 366, 87.4%) and a mean age of 52.7±13.1 years. The high-
est incidence rates for ADRs were reported for tocilizumab, rituximab and inf-
liximab with 28.8, 23.1 and 13.3 reports per 100 patient-years respectively. The 
most frequent were “Elevated transaminase levels” and “Dyspepsia”. Overall, 
87.7% of ADRs were type A; 36.6% were classified as mild, 40.7% as moderate 
and 22.7% were severe. As a result, 73.2% of patients who experienced an ADR 
stopped taking their drugs. cOnclusiOns: the occurrence of ADRs in patients 
treated for rheumatoid arthritis is common, especially in those associated with 
the use of biotechnologically produced anti-rheumatic drugs. This should be 
emphasized in reports and monitoring is needed to reduce the risks in these 
patients.
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Objectives: Patients with low-energy hip fracture represent a high-risk group 
for subsequent hip fractures. Our nationwide study focused on the effect of 
demographic and clinical factors on the risk of contralateral hip fractures in 
Hungarian men over 60 years. MethOds: The retrospective observational 
cohort study based on data of the Hungarian National Health Insurance Fund. 
Men aged 60 years and over diagnosed with primary femoral neck fracture in 
year 2000 were included in the study. The incidence of contralateral fractures 
was investigated between 01 January 2000 and 31 December 2008. Occurrence of 
secondary hip fractures was analyzed in relation to patients’ age, place of living, 
hospital providing treatment for primary hip fracture, type of primary fracture, 
comorbidities, type of surgical intervention for primary fracture and survival 
time. To evaluate the prognostic factors multivariate Cox proportional hazard 
regression and Kaplan-Meier survival analysis were used. Results: 917 patients 
matched the study criteria. 49 secondary fractures (5.34%) occurred during the 
observation period. The incidence density of secondary fractures was 0.13 cases 
per person-year, and the annual distribution showed that the highest incidence 
occurred in the second year (1.21%). Increasing age (years, HR: 1.06, p= 0.001, CI: 
1.02- 1.09) and place of living (town vs. village, HR: 2.82, p= 0.022, CI: 1.16- 6.84) 
were found as risk factor of subsequent hip fractures. Log rank test revealed no 
significant difference (p= 0.056) between the survival time of patients living in 
village (mean survival time: 1456 days) and in towns (mean survival time: 1481 
days). cOnclusiOns: We demonstrated the increased risk of subsequent hip 
fracture in men with higher age and living in towns. Considering that there was 
no difference in the survival time, there is a need to identify lifestyle factors influ-
encing the incidence of subsequent hip fractures in men living in village and in 
towns.
27 systematic reviews and health technology assessments were included, 30 clinical 
trials were extracted which the control and intervention arms were treated with 
methotrexate. The results of mixed treatment comparison revealed that tofacitinib 
displays similar safety than adalimumab, certolizumab, infliximab, etanercept, goli-
mumab, rituximab, tocilizumab and abatacept in occurrence of serious adverse 
events and serious infections due to not having statistically significance differences. 
In the outcome of withdrawal due to adverse events, etanercept showed less prob-
ability of occurrence than tofacitinib (OR= 2.21, IC95%: 1.02-4.03), regarded to other 
biological DMARDs, they presented the same risk than tofacitinib. cOnclusiOns: 
The results of mixed treatment comparison indicated that tofacitinib is similarly 
safe than biological DMARDs considering the occurrence of serious adverse events 
and serious infections.
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Objectives: Evaluate factors and reasons associated with switching from bio-
logic disease-modifying anti-rheumatic drugs (bDMARD) in Kaiser Permanente 
Southern California (KPSC) experienced RA patients; evaluate RA related health 
care resource utilization (HCRU) and costs associated with bDMARD switch-
ing. MethOds: A retrospective database study was conducted using KPSC 
patients greater than or equal to 18 years of age and with a diagnosis of RA (ICD-9 
714.xx). The identification period was from 01/01/2009 to 12/31/2012. The index 
date was defined as the first identified bDMARD prescription during the identi-
fication period. Patients were on the same index bDMARD for 24 months prior 
to index date and were followed up for 12 months post-index. Patients were cat-
egorized into a switch and a non-switch group during follow up. A multivariate 
regression analysis was conducted to evaluate factors associated with patients 
switching versus not switching. Chart notes were reviewed 30 days prior and 30 
days post switch date to identify reasons for switching. RA related HCRU and costs 
were calculated for 12 months pre/post-index for both groups. Results: 1,753 
patients were identified (5% switchers, and 95% non-switchers). Factors associated 
with bDMARD switching were: obesity, Charlson comorbidity index (CCI) score ≥ 2, 
narcotics or NSAIDS use, non-adherence, and higher outpatient use in the prior 
6 months. Over 40% of patients switched due to adverse events, lack or loss of 
efficacy. Patients who switched had higher RA related pre/post-index outpatient 
visits and higher 12 months pre/post-index outpatient visit costs versus those 
patients that did not switch. cOnclusiOns: Previous studies have evaluated 
bDMARD switching patterns in RA patients; however these unique data from this 
integrated healthcare system highlights reasons associated with bDMARD switch-
ing. Reasons associated with bDMARD switching included medication adverse 
events, and lack/loss of efficacy. RA Patients who switched bDMARD had higher 
RA related outpatient HCRU and costs.
PMs4
factors anD reasons associateD With sWitching in rheuMatoiD 
arthritis Patients neWly initiateD on Biologic DMarDs anD 
iMPact on health care resource utilization in a ManageD care 
organization
Rashid N.1, Aranda G.2, Li Z.1, Guerrero V.1, Nadkarni A.2, Patel C.2
1Kaiser Permanente, SCAL Region, Downey, CA, USA, 2BMS, Plainsboro, NJ, USA
Objectives: Evaluate factors and reasons associated with switching from initial 
biologic disease-modifying anti-rheumatic drugs (bDMARDs) in Kaiser Permanente 
Southern California (KPSC) RA patients; to evaluate RA related healthcare resource 
utilization (HCRU) and cost associated with bDMARD switching. MethOds: A ret-
rospective database study from time period 01/01/2007 to 12/31/2012 was used to 
identify KPSC patient’s ≥ 18 years of age and with a diagnosis of RA (ICD-9 714.xx). 
The index date was defined as the first bDMARD prescription with no prior history 
of bDMARD use 12 months pre-index date. Patients were followed up for 12 months 
post-index and were categorized into a switch group and a non-switch group dur-
ing follow up. A multivariate regression analysis was conducted to evaluate factors 
associated with bDMARD switching. Chart notes were reviewed 30 days prior and 
30 days post bDMARD switch to identify reasons for switching. RA related HCRU 
and costs were calculated for 12 months pre/post-index for both groups. Results: 
2,171 patients were identified (12% switchers, and 88% non-switchers). The aver-
age time for patients to switch was 110 days (SD + 95.5). Differences in base-
line characteristics included more use of corticosteroids, narcotics, and higher 
ER and outpatient visits in the switch group. Factors associated with bDMARD 
switching were: female gender, obesity, corticosteroids use, other conventional 
DMARD use, higher ER/outpatient use in the prior 6 months, and patients initi-
ated on Etanercept. Over 70% of patients switched due to adverse events, lack 
or loss of efficacy. Patients who switched had higher RA related cost during 12 
months pre/post-index compared to the non-switch group. cOnclusiOns: This 
is a unique study that used robust data from an integrated healthcare system 
to evaluate reasons associated with bDMARD switching in this RA population. 
Reasons associated with bDMARD switching included medication adverse events, 
and lack/loss of efficacy; bDMARD switchers had significantly higher RA related 
costs.
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